MTOR

Aadi Bioscience to Announce First Quarter 2022 Financial Results on May 12, 2022

Retrieved on: 
Thursday, April 28, 2022
TSC2, Adult, Calendar, Patient, Nasdaq, FDA, GLOBE, PDT, TSC1, Cancer, Aadi, Perivascular epithelioid cell tumour, Telephone, EDT, Webcast, Pharmacology, MTOR, Safety, Pharmaceutical industry

LOS ANGELES, April 28, 2022 (GLOBE NEWSWIRE) -- Aadi Bioscience, Inc. (Nasdaq: AADI), a biopharmaceutical company focused on developing and commercializing precision therapies for genetically-defined cancers with alterations in mTOR pathway genes, today announced that it will report results for the first quarter 2022 before market open on Thursday, May 12, 2022.

Key Points: 
  • LOS ANGELES, April 28, 2022 (GLOBE NEWSWIRE) -- Aadi Bioscience, Inc. (Nasdaq: AADI), a biopharmaceutical company focused on developing and commercializing precision therapies for genetically-defined cancers with alterations in mTOR pathway genes, today announced that it will report results for the first quarter 2022 before market open on Thursday, May 12, 2022.
  • Aadi management will then host a conference call and webcast at 8:30 am EDT (5:30 am PDT) to discuss the results as well as provide a corporate update.
  • A replay of the call will also be available through Aadis website within the Investors & News/Event Calendar section.
  • Aadi Bioscience, Inc. is a biopharmaceutical company focused on precision therapies for genetically-defined cancers.

Aadi Bioscience to Participate at the Jefferies “Biotech on the Bay” Summit

Retrieved on: 
Monday, April 18, 2022
Pharmacology, Adult, NASDAQ, TSC2, Perivascular epithelioid cell tumour, GLOBE, Patient, MTOR, Neoplasm, Jefferies, Founder, TSC1, Safety, FDA, Cancer, Pharmaceutical industry, Aadi

The Aadi executive teamwill be available for one-on-one meetings throughout the conference.

Key Points: 
  • The Aadi executive teamwill be available for one-on-one meetings throughout the conference.
  • Please contact your sales representative at Jefferies to register for a meeting with the company.
  • Aadi is a biopharmaceutical company focused on precision therapies for genetically-defined cancers.
  • More information on Aadis development pipeline is available on the Aadi website at www.aadibio.com .

Aadi Bioscience Announces Data Presentation on incidence of TSC1 and TSC2 Alterations in Advanced Cancers at the Annual Meeting of the American Association for Cancer Research (AACR)

Retrieved on: 
Friday, April 8, 2022
Private Securities Litigation Reform Act, Sarcoma, DFCI, Risk, University, TSC2, Find, MD Anderson Cancer Center, BRAF, TSC1, MSK, Surveillance, Forward-looking statement, Kidney, HER2, Adult, Pharmacology, KRAS, Cancer, AACR, Research, PIK3CA, American Association, Memorial Sloan Kettering Cancer Center, Neoplasm, Incidence, Failure, Poster, The Cancer Genome Atlas, SEER, Association, Dana–Farber Cancer Institute, Safety, Residency, Perivascular epithelioid cell tumour, Annual general meeting, BWH, COVID-19, GLOBE, TCGA, MTOR, Nonsense, FDA, LOS, Patient, Medical imaging, Pharmaceutical industry, Brigham, Aadi, Epidemiology

LOS ANGELES, April 08, 2022 (GLOBE NEWSWIRE) -- Aadi Bioscience, Inc. (“Aadi”) (Nasdaq: AADI), a biopharmaceutical company focused on developing and commercializing precision therapies for genetically-defined cancers with alterations in mTOR pathway genes, today announced the presentation of a poster (#5799) at the Annual Meeting of the American Association for Cancer Research (AACR), being held April 8-13, 2022 in New Orleans, LA. The research that was presented quantifies the type and number of advanced cancer patients with malignant tumors carrying TSC1 or TSC2 alterations.

Key Points: 
  • The research that was presented quantifies the type and number of advanced cancer patients with malignant tumors carrying TSC1 or TSC2 alterations.
  • TSC1 alterations were most frequent in bladder, kidney, and lung squamous cell cancers, while TSC2 alterations were most frequent in hepatobiliary, ovarian, and soft tissue sarcomas.
  • Aadi cautions you that certain statements included in this press release that are not a description of historical facts are forward-looking statements.
  • This caution is made under the safe harbor provisions of the Private Securities Litigation Reform Act of 1995.

MERITOR INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Meritor, Inc. - MTOR

Retrieved on: 
Thursday, April 7, 2022
Legal, Professional Services, NYSE, Company, LLC, MTOR, Sale, Cummins, CMI, KSF, Meritor

and the law firm of Kahn Swick & Foti, LLC (KSF) are investigating the proposed sale of Meritor, Inc. (NYSE: MTOR) to Cummins Inc. (NYSE: CMI).

Key Points: 
  • and the law firm of Kahn Swick & Foti, LLC (KSF) are investigating the proposed sale of Meritor, Inc. (NYSE: MTOR) to Cummins Inc. (NYSE: CMI).
  • Under the terms of the proposed transaction, shareholders of Meritor will receive only $36.50 in cash for each share of Meritor that they own.
  • KSF is seeking to determine whether this consideration and the process that led to it are adequate, or whether the consideration undervalues the Company.
  • To learn more about KSF, whose partners include the Former Louisiana Attorney General, visit www.ksfcounsel.com .

Meritor Publishes 2021 Sustainability Report

Retrieved on: 
Monday, April 11, 2022
Sustainability reporting, Multimedia, Meritor, NYSE, Board, Board of directors, Knowledge, Goal, GHG, MTOR, Efficiency, New, Director, Management, Online shopping

TROY, Mich., April 11, 2022 /PRNewswire/ -- Meritor, Inc. (NYSE: MTOR) today announced that it has published its 2021 Sustainability Report which is now available on the company's website at meritor.com.

Key Points: 
  • TROY, Mich., April 11, 2022 /PRNewswire/ -- Meritor, Inc. (NYSE: MTOR) today announced that it has published its 2021 Sustainability Report which is now available on the company's website at meritor.com.
  • Highlights from this year's report include the following:
    Third party limited assurance of its scope 1 and 2 GHG emissions base year data.
  • Meritor is committed to transparency and will report progress toward these goals annually.
  • "We made significant progress in the past year on multiple sustainability efforts," said Chris Villavarayan, Meritor's chief executive officer and president.

Antengene Announces Five Upcoming Presentations at the 2022 American Association for Cancer Research Annual Meeting

Retrieved on: 
Wednesday, March 9, 2022
Biomarker, AACR, Ataxia telangiectasia and Rad3 related, Mouse, Patient, Hong Kong Stock Exchange, Company, IND, Antibody, DDR, SHP2, Survival, IMAB362, Annual report, Immunosuppression, Cancer, Mutation, Date, MUC5B, NDA, Homologous recombination, Lung cancer, AM, KRAS, Tumor microenvironment, SEHK, CDX, Adenosine, Metabolism, DNA, Border, Risk, Greater, Stomach, CD73, MTOR, American Association, NDAS, 2021 Essex County Council election, Ataxia–telangiectasia, II, ATR, Drug discovery, XPO1, Compugen (Israeli company), Time, PDX, Association, Program, AMP, Vaccine, Pharmaceutical industry, Flour

CD73 is an enzyme that is highly expressed in the tumor microenvironment and enables the degradation of AMP into adenosine, resulting in immunosuppression and cancer progression.

Key Points: 
  • CD73 is an enzyme that is highly expressed in the tumor microenvironment and enables the degradation of AMP into adenosine, resulting in immunosuppression and cancer progression.
  • In vitroassays were used to assess each compound's ability to inhibit CD73 function and reverse AMP/adenosine mediated T-cell suppression.
  • Compared to the two antibodies, ATG-037 demonstrated more potent and complete inhibitory activity of cell surface CD73 in this study.
  • Antengene Corporation Limited ("Antengene", SEHK: 6996.HK) is a leading commercial-stage R&D-driven global biopharmaceutical company focused on innovative first-in-class/best-in-class therapeutic medicines for cancer and other life-threatening diseases.

Meritor Earns Heavy Duty Trucking's Top 20 Product Award for 14Xe™ ePowertrain

Retrieved on: 
Tuesday, March 8, 2022
Industry, Exhibition, Multimedia, Fuso Trucks America, Efficiency, Georgia Featured Export Product Awards, Meritor, NYSE, New, Technology, HDT, MTOR, Knowledge, China National Heavy Duty Truck Group, Maintenance, Rail transport, Renewable energy, Online shopping

TROY, Mich., March 8, 2022 /PRNewswire/ -- Meritor, Inc. (NYSE: MTOR) today announced it has been honored in Heavy Duty Trucking Magazine's 2022 Top 20 Products Awards for its 14Xe ePowertrain, a fully integrated, all-electric drive system that launched in December 2021.

Key Points: 
  • TROY, Mich., March 8, 2022 /PRNewswire/ -- Meritor, Inc. (NYSE: MTOR) today announced it has been honored in Heavy Duty Trucking Magazine's 2022 Top 20 Products Awards for its 14Xe ePowertrain, a fully integrated, all-electric drive system that launched in December 2021.
  • "Meritor's 14Xe ePowertrain met the criteria for the award based on its innovative design, potential for bottom-line cost savings and it produces zero emissions which our industry is focused on," said Deborah Lockridge, editor in chief of Heavy Duty Trucking.
  • As part of Meritor's Blue Horizon advanced technology portfolio, the 14Xe ePowertrain is designed to provide efficiency, performance, weight savings and enhanced space utilization.
  • It can be adapted to fit various powertrain needs based on vehicle application and duty cycle spanning Class 5-8 commercial vehicles.

Clarience Technologies Forms Technology Alliance with Meritor to Explore Future Connectivity Solutions in Commercial Transportation

Retrieved on: 
Tuesday, March 8, 2022
Safety, Industry, Software as a service, Research, Acquisition, Efficiency, IOT, MTOR, Solution, Technology, Software, Knowledge, Transport, Cryptocurrency

With telematics solutions expected to take off as electric and autonomous technologies take hold, Road Ready is confident it will be ready to meet demand.

Key Points: 
  • With telematics solutions expected to take off as electric and autonomous technologies take hold, Road Ready is confident it will be ready to meet demand.
  • Road Ready, a Clarience Technologies brand, is a vertically integrated advanced telematics and smart fleet solutions SaaS provider based in Southfield, Michigan.
  • Clarience Technologies focuses on developing vehicle and fleet management technology innovations the commercial vehicle, passenger car, recreational off-roadmachine,and pleasure craft markets.
  • Meritor, Inc.is a leading global supplier of drivetrain, mobility, braking, aftermarket and electric powertrain solutions for commercial vehicle and industrial markets.

Lifshitz Law PLLC Announces Investigation of MTOR, OBNK, SJI, and TEN

Retrieved on: 
Sunday, March 6, 2022
Sale, TEN, MTOR, SJI, Kerala Infrastructure Investment Fund Board, Hewlett, Cummins, Telephone, Advertising, Life insurance, Online shopping, Financial adviser

Lifshitz Law PLLC announces investigation into possible breach of fiduciary duties in connection with the sale of MTOR to Cummins Inc. for $36.50 in cash per share of MTOR owned.

Key Points: 
  • Lifshitz Law PLLC announces investigation into possible breach of fiduciary duties in connection with the sale of MTOR to Cummins Inc. for $36.50 in cash per share of MTOR owned.
  • Lifshitz Law PLLC announces investigation into possible breach of fiduciary duties in connection with the merger of OBNK and BT Holdings, Inc.
  • Lifshitz Law PLLC announces investigation into possible breach of fiduciary duties in connection with the sale of SJI to Infrastructure Investments Fund for $36.00 in cash per share of SJI owned.
  • The law firm responsible for this advertisement is Lifshitz Law PLLC 1190 Broadway, Hewlett, New York 11557, Tel: (516)493-9780.

Meritor Announces Collaboration with ConMet eMobility to Enable Zero-Emission Trailers

Retrieved on: 
Thursday, March 3, 2022
Meritor, Trailer, Industry, Science, Knowledge, Solution, Motor vehicle, NYSE, Efficiency, Multimedia, Refrigeration, MTOR, Engineering, Technology, New, Transport, Heavy equipment, Renewable energy, Online shopping

The companies will also continue to jointly evaluate the application of industry leading, complementary advanced technologies that address evolving e-mobility market trends.

Key Points: 
  • The companies will also continue to jointly evaluate the application of industry leading, complementary advanced technologies that address evolving e-mobility market trends.
  • "This agreement with ConMet eMobility demonstrates our focus on the future of advanced transportation technology and is another example of an eOptimized product solution by Meritor that brings tire management and zero-emission solutions to the commercial vehicle industry.
  • Founded in 1964, ConMet innovation has been critical in designing, engineering, and manufacturing revolutionary technologies for trucks and trailers.
  • ConMet eMobility was established in 2020 to address the needs and challenges of clean energy technology.